Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International



Home > Press > UCSB Chosen for Two NIH Nanotechnology Grants

Abstract:
UCSB is Only University to Participate in Two PEN Nanotech Grants

Developing Novel Technologies to Diagnose and Treat Diseases of the Heart and Lungs

UCSB Chosen for Two NIH Program of Excellence (PEN) in Nanotechnology Grants

Santa Barbara, CA | July 14, 2005

The University of California, Santa Barbara, has been chosen to participate in two interdisciplinary, multi-university research efforts as a Program of Excellence in Nanotechnology (PEN). The awards by the National Heart, Lung and Blood Institute of the National Institutes of Health (NIH) are part of NIH's strategy to accelerate progress in medical research through innovative technology and interdisciplinary research. Both research efforts bring together bioengineers, materials scientists, biologists and physicians working in interdisciplinary teams.

  1. UCSB will be working with Washington University in St. Louis and UC Berkeley, under a $12.5 million grant, to develop nanoscale agents to provide early diagnosis and treatment of pulmonary artery disease. At UCSB, the project is being led by Professor Craig Hawker, Director of the Materials Research Lab.
  2. UCSB will be teaming with The Burnham Institute and Scripps Research Institute, both of La Jolla, Calif., to apply a $13 million grant to develop ways to use nanotechnologies in the design of new ways to detect, monitor, treat and eliminate vulnerable plaque, the probable cause of death from sudden cardiac arrest. UCSB professors participating in the project include Matthew V. Tirrell, PhD, Dean of the college of Engineering and professor of chemical engineering; Andrew N. Cleland, PhD, associate professor pf physics; Patrick Daughterty, PhD, associate professor of chemical engineering; Samir Mitragotri, PhD, assistant professor of chemical engineering; and Joseph Zasadzinski, PhD, professor of chemical engineering.

The team coordinated by Profess Karen L. Wooley at Washington University in St. Louis and led at UCSB by Professor Craig Hawker will use nanoscale materials as carriers for diagnostic systems and to deliver therapeutic agents. A major goal will be to develop ways to trigger a breakdown of the nanoparticles after a payload, such as a drug or antiviral agent, is delivered to a diseased zone. Targeted nanoparticles will search out arteries that are under stress or are diseased.

The group coordinated by The Burnham Institute will build "delivery vehicles" than can be used to transport drugs, imaging agents and nano-devices directly to locations where there is vulnerable plaque; design molecular nano-stents to physically stabilize vulnerable plaque and replace its fibrous cap with an anti-adhesive, anti-inflammatory surface; devise molecular switches that can sense and respond to the pathophysiology of atheroma (fatty deposits on arterial walls); and develop bi-nanoelectromechanical systems (called BioNEMS) that can sense and respond to vulnerable plaque, ultimately providing diagnostic and therapeutic capability.

####

Contact:
Barbara Bronson Gray
818.889.5415
bbgray@sbcglobal.net

Copyright © UCSB

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

Investments/IPO's/Splits

Daikin Industries becomes OCSiAl shareholder July 27th, 2021

180 Degree Capital Corp. Reports +14.2% Growth in Q1 2021, $10.60 Net Asset Value Per Share as of March 31, 2021, and Developments From Q2 2021 May 11th, 2021

INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021

180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021

Nanomedicine

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery: NYU Abu Dhabi researchers develop novel covalent organic frameworks for precise cancer treatment delivery September 13th, 2024

Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024

Nanobody inhibits metastasis of breast tumor cells to lung in mice: “In the present study we describe the development of an inhibitory nanobody directed against an extracellular epitope present in the native V-ATPase c subunit.” August 16th, 2024

Announcements

Nanotechnology: Flexible biosensors with modular design November 8th, 2024

Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024

Turning up the signal November 8th, 2024

Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project